Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 23

Showing 23 citing articles:

Clozapine as an E3 Ligand for PROTAC Technology
Reina Takano, Nobumichi Ohoka, Takashi Kurohara, et al.
ACS Medicinal Chemistry Letters (2025)
Closed Access
Targeting intracellular cancer proteins with tumor‐microenvironment‐responsive bispecific nanobody‐PROTACs for enhanced therapeutic efficacy
Changping Deng, Jiacheng Ma, Yuping Liu, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access
Synthesis of α-(azidomethyl)glutarimide and its applicationin construction of potential Cereblon ligands <em>via</em> the CuAAC reaction
Liliya R Khuzhakhmetova, Anna A Ananeva, Grigory Kantin, et al.
Mendeleev Communications (2025) Vol. 35, Iss. 1, pp. 69-72
Closed Access
Recent Advances on Targeting Proteases for Antiviral Development
Pedro Henrique Oliveira Borges, Sabrina Baptista Ferreira, Floriano Paes Silva
Viruses (2024) Vol. 16, Iss. 3, pp. 366-366
Open Access | Times Cited: 3
Recent insights of PROTAC developments in inflammation-mediated and autoimmune targets: a critical review
Mary Sravani Galla, Nitika Sharma, Priyanka Mishra, et al.
RSC Medicinal Chemistry (2024) Vol. 15, Iss. 8, pp. 2585-2600
Closed Access | Times Cited: 3
PROteolysis‐Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives
André T. S. Vicente, Jorge A. R. Salvador
MedComm (2024) Vol. 5, Iss. 6
Open Access | Times Cited: 1
BET-directed PROTACs in triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-436
Maryana Teufelsbauer, Sandra Stickler, Marie-Therese Eggerstorfer, et al.
Breast Cancer Research and Treatment (2024) Vol. 208, Iss. 1, pp. 89-101
Open Access | Times Cited: 1
Bromodomain Protein-directed Agents and MYC in Small Cell Lung Cancer
Gerhard Hamilton, Sandra Stickler, Barbara H. Rath
Current Cancer Drug Targets (2024) Vol. 24, Iss. 9, pp. 930-940
Closed Access | Times Cited: 1
PROTAC Beyond Cancer- Exploring the New Therapeutic Potential o f Proteolysis Targeting Chimeras
Ritesh P. Bhole, S. Patil, Harshad S. Kapare, et al.
Current Topics in Medicinal Chemistry (2024) Vol. 24, Iss. 23, pp. 2050-2073
Closed Access | Times Cited: 1
Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer
Ranjan Kumar Acharyya, Rohan Kalyan Rej, Biao Hu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 21, pp. 19010-19037
Closed Access | Times Cited: 1
Targeted degradation of extracellular mitochondrial aspartyl-tRNA synthetase modulates immune responses
Benjamin S. Johnson, Daniela Farkas, Rabab El-Mergawy, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access
Acetyl-CoA Carboxylase Proteolysis-Targeting Chimeras: Conceptual Design and Application as Insecticides
Qi Xu, Hao Feng, Zhong Li, et al.
Journal of Agricultural and Food Chemistry (2024) Vol. 72, Iss. 34, pp. 18809-18815
Closed Access
Proteolysis Targeting Chimera (PROTACs): An Attractive Technology in CVD Therapeutics—Opportunities and Challenges
Dhruv Gupta, Nidhi Khedpande, Kalyani Barve
(2024), pp. 347-365
Closed Access
Between Theory and Practice: Computational/Experimental Integrated Approaches to Understand the Solubility and Lipophilicity of PROTACs
Andrea Venturi, Stefano Di Bona, Jenny Desantis, et al.
Journal of Medicinal Chemistry (2024)
Closed Access
SMURF1: A promising target for colon cancer therapy
Xiufang Xiong, Yongchao Zhao, Yi Sun
Protein & Cell (2024)
Open Access
Bavdegalutamide (ARV-110): a potent PROTAC androgen receptor degrader for the treatment of metastatic-castration resistant prostate cancer
Lin Ma, Xin Han
Elsevier eBooks (2024), pp. 357-378
Closed Access
PROTAC and ProTide Strategies in Drug Design
Manali Mukherjee
(2024), pp. 457-475
Closed Access
Strategy and Design of In Situ Activated Protein Hydrolysis Targeted Chimeras
Mei-Yu Lv, Da‐Yong Hou, Shaowei Liu, et al.
ACS Nano (2024) Vol. 19, Iss. 1, pp. 101-119
Closed Access
Discovery of a Natural Ent-Kaurene Diterpenoid Oridonin as an E3 Ligase Recruiter for PROTACs
Jie Huang, Xuekun Fu, Fang Qiu, et al.
Journal of the American Chemical Society (2024)
Closed Access
Novel IRAK4 Inhibitors for Treating Asthma, COPD, Cancer, Autoinflammatory Diseases, and Autoimmune Diseases
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 12, pp. 1617-1618
Closed Access | Times Cited: 1
Splicing DNA Damage Adaptations for the Management of Cancer Cells
Arun Kumar Singh, Deepika Yadav, Rishabha Malviya
Current Gene Therapy (2023) Vol. 24, Iss. 2, pp. 135-146
Closed Access | Times Cited: 1
Recent advancements in targeted protein knockdown technologies—emerging paradigms for targeted therapy
Mansi Joshi, Pranay Dey, Abhijit De
Exploration of Targeted Anti-tumor Therapy (2023) Vol. 4, Iss. 6, pp. 1227-1248
Open Access | Times Cited: 1
Page 1

Scroll to top